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Tenascins are a family of multifunctional glycoproteins found in the extracellular matrix
of chordates. Two of the tenascins, tenascin-C and tenascin-W, form hexabrachions.
In this review, we describe the discovery and domain architecture of tenascin-W, its
evolution and patterns of expression during embryogenesis and in tumors, and its
effects on cells in culture. In avian and mammalian embryos tenascin-W is primarily
expressed at sites of osteogenesis, and in the adult tenascin-W is abundant in certain
stem cell niches. In primary cultures of osteoblasts tenascin-W promotes cell migration,
the formation of mineralized foci and increases alkaline phosphatase activity. Tenascin-
W is also prominent in many solid tumors, yet it is missing from the extracellular matrix
of most adult tissues. This makes it a potential candidate for use as a marker of tumor
stroma and a target for anti-cancer therapies.
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INTRODUCTION
Tenascins are extracellular matrix glycoproteins that have a characteristic domain organization. At
the N-terminus tenascins have a region that permits trimerization through coiled–coil interactions,
and some tenascins have N-terminal cysteines that can support the covalent linking of two trimers
to form a hexabrachion. From N-terminal to C-terminal this multimerization region is followed by
one or more epidermal growth factor (EGF)-like domains, a series of fibronectin type III (FNIII)
domains, and a fibrinogen-related domain (Chiquet-Ehrismann and Tucker, 2011).
In tetrapods there are four tenascin genes that encode tenascin-C, tenascin-R, tenascin-X, and
tenascin-W (Chiquet-Ehrismann and Tucker, 2011). The best studied of these is tenascin-C, which
was also the first tenascin to be discovered (Chiquet-Ehrismann and Tucker, 2011; Midwood
et al., 2016). Tenascin-C is widely expressed in the embryo at sites of epithelial–mesenchymal
interactions and around motile cells, including neural crest cells and migrating neuroblasts and
glial precursors. It is also found at sites of branching morphogenesis and in developing smooth
muscle, bone and cartilage. In the adult, the expression of tenascin-C is more limited, but it is still
expressed at high levels in tendons and in some stem cell niches (Chiquet-Ehrismann et al., 2014).
Tenascin-R has a more restricted pattern of expression. It is primarily found around subsets of
glia and in perineural nets in the developing and adult central nervous system (Dzyubenko et al.,
2016). Tenascin-X is found widely in loose connective tissue in both the late stages of embryonic
development and in the adult, often displaying expression that is mostly complementary to that of
tenascin-C (Valcourt et al., 2015).
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This review will concentrate on the fourth and final member
of the tenascin gene family to be identified: tenascin-W. We
will summarize its discovery and domain architecture, patterns
of expression, effects on cells in culture, relationships to other
tenascins, as well as its roles in cancer and potential for
translational use.
TENASCIN-W BASICS
Discovery and Domain Organization
Tenascin-W was first identified in the zebrafish (Weber et al.,
1998). The “W” is most likely an eponymous reference to the
last name of its discoverer. In situ hybridization with zebrafish
embryos demonstrated that tenascin-W is expressed by migrating
sclerotome cells and neural crest cells, together with tenascin-
C. The zebrafish tenascin-W described by Weber et al. (1998)
has 4 EGF-like domains and 5 FNIII domains, and a predicted
molecular weight of 103 kDa. A sixth predicted FNIII domain is
found in the genomic sequence of zebrafish tenascin-W which
may be available for alternative splicing (Tucker et al., 2006),
though alternative splicing of tenascin-W has not been reported.
The homolog of tenascin-W in the mouse was originally
named tenascin-N (Neidhardt et al., 2003), which explains why
this term and its abbreviation TNN is still encountered in the
literature and sequence repositories. The murine homolog was
assumed to be a novel tenascin since it has 12 FNIII domains
instead of the 5 previously reported in the zebrafish. However,
sequence alignment studies reveal that the third FNIII domain of
tenascin-W, which is encoded on a single exon, has duplicated
repeatedly over the course of evolution (Tucker et al., 2006).
Consequently, the number of FN III domains, and hence the
size of tenascin-W, can vary significantly from species to species
(Figure 1). Synteny also supports the argument that murine
tenascin-N is, in fact, tenascin-W: in fish, birds and mammals
the tenascin-W gene is found adjacent to the tenascin-R gene
(Tucker et al., 2006). In the years that followed the publication
of these observations, all peer-reviewed studies focusing on this
form of tenascin refer to it as “tenascin-W,” and not tenascin-N.
Like tenascin-C, and unlike other tenascins, tenascin-W forms
hexabrachions (Scherberich et al., 2004). There is no evidence
supporting the formation of tenascin-C/tenascin-W heteromers.
The functions of some of the domains of tenascin-W have
been determined experimentally, and potential roles can also be
hypothesized from published work with tenascin-C. For example,
the FNIII domains appear to contain integrin binding sites (see
below), and the fibrinogen-related domains of tenascin-W and
tenascin-C share significant similarities and are able to bind
and activate Toll-like receptor 4 (Zuliani-Alvarez et al., 2017).
Tenascin-W, like tenascin-C, can bind Wnt3a (Hendaoui et al.,
2014), but the domain where this binding takes place is unknown.
Finally, the EGF-like domains of tenascin-W are nearly identical
to those of tenascin-C, and the latter have been shown to be able
to activate EGF receptors (Swindle et al., 2001; Fujimoto et al.,
2016). Future studies should be directed to see if these properties
are unique to tenascin-C, or if tenascin-W may share these and
other functional domains with its larger paralog.
Evolution
While some extracellular matrix molecules like collagens and
thrombospondins evolved with the first metazoans (Özbek et al.,
2010), others evolved more recently. Tenascins are an example of
a family of extracellular matrix molecules that evolved with the
first chordates; they are not present in echinoderms, ecdysozoa,
or lophotrochozoa (Tucker and Chiquet-Ehrismann, 2009a).
A single tenascin gene is found in amphioxus and tunicates,
FIGURE 1 | Domain organization of tenascin-W. Tenascin-W has a region near its N-terminus that promotes trimerization (purple); two trimers become covalently
linked to form a hexabrachion. Tenascin-W from different species can have different molecular weights as the third FNIII domain (yellow), which is encoded on a
single exon, has been duplicated a number of times over the course of evolution. Tetraodon and Takifugu are genera of pufferfish. Gallus is the genus of the chicken
and Mus is the genus of the mouse. FReD, fibrinogen-related domain.
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yet neither of these groups has a fibronectin gene (Adams
et al., 2015). In lampreys and cartilaginous fish there are two
tenascins, and in the latter group these are clearly tenascin-
C and tenascin-R. But in bony fish the full complement of
four tenascins are seen, including tenascin-W. Thus, tenascin-
W apparently evolved together with a bony skeleton, which is
intriguing considering its primary sites of expression and its
effects on cells in vitro (see below).
Expression at Sites of Osteogenesis and
Around Smooth Muscle
Following the pioneering study of tenascin-W expression in the
zebrafish described above, the expression of tenascin-W was
studied in the mouse and chicken. In contrast to tenascin-C,
tenascin-W is detected by immunohistochemistry at relatively
late stages of development in the chicken. Starting around
embryonic day (E) 8, tenascin-W immunostaining is found in
areas of osteogenesis and around a subset of smooth muscles
in the developing gut (Meloty-Kapella et al., 2006). Later in
development it is seen in the cartilaginous skeleton of the heart.
Antibodies to tenascin-W label fibrils in the extracellular matrix
and it usually, but not always, co-localizes with tenascin-C in
these fibrils. Co-localization with tenascin-C is nicely illustrated
in developing scleral ossicles in the E10 eye (Figure 2A).
The tenascin-W found at sites of osteogenesis likely comes
from the osteoblasts themselves, as cultured primary chicken
osteoblasts elaborate tenascin-W matrices in the presence of
bone morphogenetic protein (BMP) 2 (Figure 2B). The literature
lacks, however, detailed descriptions of where tenascin-W is
found in situ: is it made by osteoblasts only, or is it made by
osteoblast precursor cells as well? The latter is possible, and
FIGURE 2 | The expression of tenascin-W (TNW). (A) Double-label immunohistochemical localization of tenascin-C (TNC) and TNW in the scleral ossicles of an E10
chicken. TNW is commonly expressed at sites of osteogenesis, where it is typically found in the subset of the extracellular matrix labeled with antibodies to TNC.
(B) After 6 days in culture primary chicken osteoblasts elaborate a TNW-rich extracellular matrix in the presence of BMP2. (C) Anti-TNC and anti-TNW both label
fibrils in the trabecular region (tr) of adult mouse whisker follicles between the bulge (b) and the capsule (c). TNW-positive fibrils are typically, but not always, a subset
of the TNC-positive fibrils. (D) The TNW-rich trabecular region contains cd34-positive stem cells.
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tenascin-W transcripts are detected in MC3T3-E1 preosteoblasts
(Schroeder et al., 2007).
During mouse development tenascin-W expression
has been studied with both in situ hybridization and
immunohistochemistry. As in the chicken, tenascin-W in
the mouse is expressed at sites of osteogenesis and in subsets of
smooth and skeletal muscle during development (Scherberich
et al., 2004). It is first seen in the maxillary processes at
E11.5. While its expression at sites of osteogenesis typically
overlaps extensively with the expression of tenascin-C, its
expression in smooth muscle sometimes overlaps and sometimes
does not. For example, both tenascin-C and tenascin-W are
found in the muscularis mucosa of the stomach at E15.5,
but at this stage of development only tenascin-W is found
in the muscularis externa. As in the chicken, tenascin-W
expression is not observed in the developing nervous system
of the mouse (Scherberich et al., 2004). The expression of
tenascin-W in a subset of skeletal muscles is evident both from
immunohistochemistry (Scherberich et al., 2004) and microarray
studies (Fischer et al., 2005). In the mouse, tenascin-W is
expressed in developing teeth (Scherberich et al., 2004), and
this has been confirmed by microarray analysis of RNA from
laser-captured tissues (Sun et al., 2012).
In the adult chicken tenascin-W is detected in the interstitial
matrix of the testis and lining brain ventricles (Meloty-Kapella
et al., 2006). The latter immunostaining is the only expression
of tenascin-W that is related to the nervous system. In the adult
mouse tenascin-W expression is observed in periostea, kidney,
spleen (Neidhardt et al., 2003; Scherberich et al., 2004) and stem
cell niches (see below). Tenascin-W is also seen in some adult
human periostea (Tucker et al., 2016).
Expression in Stem Cell Niches
The first evidence that tenascin-W might play a role in stem cell
niches came from studies of its expression in the adult mouse
by Scherberich et al. (2004). They observed anti-tenascin-W
immunostaining in the corneal limbus and at the base of the
cusps of the aortic valves. The limbus niche contains corneal
epithelial stem cells (Castro-Muñozledo, 2013), and the cusp base
is a potential site of islet1-expressing neural crest-derived stem
cells (Engleka et al., 2012). The expression of tenascin-W in bone
may also be related to stem cell niches, but this will require more
detailed studies for confirmation. Tenascin-W is not detected
with immunohistochemistry in the stem cell niche of intestinal
crypts (Scherberich et al., 2004; Meloty-Kapella et al., 2006).
One of the most prominent sites of tenascin-W expression in
the adult mouse is in hair and whisker follicles (Tucker et al.,
2013). In hair follicles tenascin-W is found in a ring just proximal
and immediately adjacent to the keratin-15-positive bulge. This
region corresponds to the location of nestin-positive stem cells
(Amoh et al., 2010) that take part in the cyclic regeneration of hair
shafts. In the much larger whisker follicle, tenascin-W-positive
fibrils are found in the trabecular region. Tenascin-C is also found
in this region, and there is extensive, but not complete, overlap
in the tenascin-W and tenascin-C-positive fibrils (Figure 2C).
The region inside the whisker follicle capsule where tenascin-
W is found is filled with cd34-positive stem cells (Figure 2D).
These cells may be mast cell progenitors, or they may be a
population of stem cells like those near the keratin-15-positive
bulge of hair follicles.
Tenascin-W expression has been found to be up- or
downregulated in many studies using microarrays. A search of
the 2913 datasets published on the GEO website1 found by
searching for “TNN and tenascin” (TNN is the genetic shorthand
for both tenascin-W and troponins) revealed 33 examples
where tenascin-W was consistently up- or downregulated
(Supplementary Table S1). Many of these are related to tenascin-
W expression in dense connective tissue and in stem cell niches;
others are related to tenascin-W in cancer (see below).
THE CELL BIOLOGY OF TENASCIN-W
Tenascin-W as an Adhesion
Modulatory Protein
Adhesion modulation can influence cell motility, proliferation
and differentiation. Tenascin-C is a classic adhesion modulatory
protein (Chiquet-Ehrismann and Tucker, 2011). In vitro, cells can
attach to tenascin-C, but they typically fail to spread and form
focal adhesions. Similarly, cells that have formed focal adhesions
on a substratum coated with fibronectin will lose their focal
adhesions if tenascin-C is added to the medium. Tenascin-W
also has the potential to act as an adhesion modulatory protein.
For example, the myoblast-derived osteogenic mouse cell line
C2C12 spread and form focal adhesions and stress fibers on
fibronectin, but C2C12 cells remain rounded or stellate and fail
to form focal adhesions or stress fibers when cultured in the
presence of tenascin-W (Scherberich et al., 2004; Brellier et al.,
2012a). Moreover, C2C12 cells remain stellate when cultured
on fibronectin if tenascin-W is in the culture medium or if
they are cultured on a mixed fibronectin/tenascin-W substratum
(Brellier et al., 2012a). Similarly, primary osteoblasts cultured
from chicken embryo calvarias spread and form stress fibers on
fibronectin but fail to spread on combinations of fibronectin
and tenascin-W (Meloty-Kapella et al., 2006). Tenascin-W does
not demonstrate adhesion modulation with all cell types. For
example, the human breast cancer cell line T47D does not
adhere to a tenascin-W-coated substratum, in contrast to dermal
fibroblast Detroit551 cells, which attach to human tenascin-
W in an integrin β1-dependent manner (Degen et al., 2007).
In addition, T47D cells are still able to adhere to a mixed
fibronectin/tenascin-W substratum, which is not the case for
fibronectin/tenascin-C substrata (Degen et al., 2007).
Effects of Tenascin-W on
Cultured Osteoblasts
Tenascin-W may have evolved in bony fish, and a prominent
and phylogenetically conserved site of tenascin-W expression
is periosteum and other sites of osteogenesis. One way of
studying the effects of tenascin-W on bone maturation is to
measure alkaline phosphatase activity in cultured osteoblasts in
1https://www.ncbi.nlm.nih.gov/geo/
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the presence of tenascin-W. When cultured in dishes coated
with 1–10 µg/ml of tenascin-W there is a significant increase
in alkaline phosphatase activity in primary calvarial osteoblasts
from the chicken (Meloty-Kapella et al., 2008). Interestingly,
no increase in activity is seen when higher concentrations of
tenascin-W are used to coat the dishes. Over time, cultured
primary osteoblasts make mineralized foci called rosettes. In
the presence of tenascin-W, significantly more rosettes form.
Tenascin-W also influences osteoblast motility in culture.
When primary osteoblasts are cultured on tenascin-W-coated
filters, significantly more cells migrate across the filter when
compared with uncoated filters or filters coated with tenascin-
C. Unlike tenascin-C, tenascin-W has no effect on primary
osteoblast proliferation.
Regulation of Tenascin-W Expression
In contrast to the other tenascins relatively little is known
about how tenascin-W expression is regulated (Chiovaro et al.,
2015a). The UCSC Genome Browser reveals a high degree of
conservation between the first non-coding exons of human
and murine tenascin-W, as well as in the region extending
up to 600 bp 5′ to the first exon. This indicates that there
are likely conserved promoters in this region, but more
experimental research is clearly needed. This region contains
both a TATA box (conserved with tenascin-C) and predicted
SMAD-binding elements, and both appear to be active (Chiovaro
et al., 2015b). Some potential transcriptional regulators and
regulatory pathways are suggested by microarray analyses,
including sonic hedgehog, Wilms tumor protein 1, and Notch
1 (Supplementary Table S1). In vitro, transforming growth
factor (TGF) β1 upregulates tenascin-W in bone marrow stem
cells (Chiovaro et al., 2015b), and BMP2 induces tenascin-
W in both C2C12 (Scherberich et al., 2004) and HC11 cells
(Scherberich et al., 2005).
Effects of Tenascin-W on Stem Cells
in vitro
Stem cells can be cultured from their niche in the trabecular
region of whisker follicles by stripping the follicle of its capsule,
cutting the whisker on either side of the niche, and putting
the whisker with the attached niche onto coated plastic dishes.
Over time, the stem cells migrate away from the niche and
their behavior and morphology can be studied (Sieber-Blum
and Hu, 2008). As seen earlier with primary osteoblasts and
C2C12 cells, these stem cells will spread and form focal adhesion
and stress fibers on fibronectin, but the cells are less spread
and have significantly fewer focal adhesions when they migrate
onto a mixed fibronectin/tenascin-W substratum (Tucker et al.,
2013). The stem cells proliferate at a greater rate in the
presence of tenascin-C, but not tenascin-W. What might the
role of tenascin-W be in the whisker follicle, and other, stem
cell niche? One might be to anchor and concentrate factors
like Wnt3a that can influence proliferation and differentiation.
Another could be to form a substratum that supports migration:
stem cells leaving the trabecular region need to migrate over
a millimeter to the whisker follicle bulb, and their pathway
is lined with tenascin-W. Insight may come from careful
analysis of the tenascin-W knockout mouse, which has yet to
be characterized.
Tenascin-W Signaling
Tenascin-W may be an integrin ligand, and some of its effects
on cells in culture may be the results of integrin-based signaling.
Scherberich et al. (2004) cultured human T98G glioblastoma-
derived cells on murine tenascin-W and assayed the ability of
function-blocking antibodies against specific integrin subunits to
inhibit this adhesion. The only antibody to block the adhesion
was an anti-β1. As a function-blocking anti-α8 was not available,
Scherberich et al. (2004) next transfected a cell line that does not
normally adhere to tenascin-W with an α8 cDNA, and found
that this induced adhesion to tenascin-W. In addition, antibodies
to the α8 integrin subunit show expression in many of the
same tissues where tenascin-W is found, including periosteum
(Scherberich et al., 2004). These observations were expanded
upon with 3T3 cells. 3T3 cells normally do not adhere to tenascin-
W, but transfecting 3T3 cells with the α8 integrin subunit
increases both their adhesion to, and motility on, tenascin-
W-coated substrata (Scherberich et al., 2005). The drawback
of such studies is that they do not show direct interactions
between the ligand and the receptor. α8β1 integrin recognizes the
tripeptide motif RGD, and an RGD is found in an exposed loop
of the second FNIII domain of mouse tenascin-W. Accordingly,
RGD-containing peptides, but not scrambled peptides, block the
adhesion of T98G cells to murine tenascin-W-coated substrata
(Scherberich et al., 2004). However, an exposed RGD is not
found in human or chicken tenascin-W. Interestingly, human
and chicken tenascin-C have an RGD motif in the third FNIII,
but the third FNIII of mouse tenascin-C does not (Adams et al.,
2015). Perhaps tenascin-C and tenascin-W share come integrin-
mediated functions and can compensate for each other. Future
studies should consider the use of murine tenascin-W with the
RGD mutated to another sequence to see if this is, in fact, the
sequence recognized by α8β1 integrin.
In summary, studies of cell-tenascin-W interactions in vitro
indicate that tenascin-W can influence cell adhesion, migration
and differentiation, but unlike tenascin-C, tenascin-W does not
appear to influence cell proliferation. Tenascin-W seems to
modulate cell adhesion in a highly cell type-specific and integrin-
dependent way, which might have relevance in the dissemination
process of cancer cells during tumor progression (see below).
TENASCIN-W IN CANCER
Tenascin-W Expression in Solid
Human Tumors
Tumor development has traditionally been viewed as a
cell-autonomous process and research was greatly focused
on neoplastic cells and the understanding of cancer cell
transformation. However, this reductionist vision has changed
over the last couple of years. It is now well established that for
the full malignant manifestation, tumor cells require a tumor-
permissive microenvironment, which is created by a complex
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interplay between cancer cells and their local environment.
Among the proteins known to be specifically expressed in tumor-
associated stroma are tenascin-C and tenascin-W. Initially,
tenascin-W was found to be overexpressed in the stroma
around murine breast tumor lesions having a high likelihood to
form metastases (Scherberich et al., 2005). Prompted by these
first observations, additional studies on the expression pattern
of tenascin-W in human biopsies followed. These analyses
revealed complete absence of tenascin-W in most normal
adult human tissues and prominent de novo expression in all
tumors investigated. Tenascin-W is overexpressed in the tumor
stroma of breast (Degen et al., 2007), colorectal (Degen et al.,
2008), brain (oligodendroglioma, astrocytoma, and glioblastoma)
(Martina et al., 2010), kidney (clear cell carcinoma, papillary
carcinoma, chromophobe renal carcinoma, and oncocytoma),
ovarian, prostate, pancreas, and lung cancers as well as in
melanomas (Brellier et al., 2012b; Figure 3). In metastatic
melanoma patients, tenascin-W is not only expressed in the
primary tumor, but it is also detected in 25% of biopsies received
from metastases from diverse locations (i.e., spleen, lung, and
skin) as well as in 38% of lymph node metastasis samples (Brellier
et al., 2012b). In the tumor stroma, tenascin-W is often found
adjacent to blood vessels co-localizing with the endothelial cell
markers cd31 and von-Willebrand-factor (Martina et al., 2010;
Brellier et al., 2012b; Figure 3).
The cellular source of tenascin-W expression in the tumor
stroma remains to be clarified. So far, all available data
suggest that tenascin-W expression is restricted to stromal
cells. In a xenograft model of breast cancer cells with bone-
specific metastatic potential, the bone marrow-derived stromal
cells exclusively expressed tenascin-W when co-cultured with
the malignant cells (Chiovaro et al., 2015b). Confirming the
concept of tenascin-W production by stromal cells, tenascin-
W is neither detectable in epithelial-derived cancer cells by
immunohistochemistry nor in various human cancer cell lines
analyzed and screened by in vitro assays. This contrasts with
tenascin-C, which can be expressed by stromal as well as cancer
cells (e.g., in gliomas) (Sivasankaran et al., 2009).
It is well established that tenascin-C is subject to alternative
splicing within its FNIII domains. Certain tenascin-C splice
variants containing additional FNIII domains are more tumor-
specific than the shortest isoform, and isoform-specific antibodies
against tenascin-C can be used as tumor markers. Although
tenascin-W shares the modular structure of tenascin-C including
a (shorter) stretch of FNIII domains, there is no evidence so far
that tenascin-W undergoes alternative splicing in physiological as
well tumorigenic conditions.
While tenascin-C and tenascin-W are often co-expressed in
the stroma of various solid tumors, certain cancers selectively
express only one of the two extracellular matrix proteins (Degen
et al., 2007, 2008). These observations suggest the existence
of common as well as independent regulatory mechanisms
responsible for tenascin-C and tenascin-W expression
(Chiquet-Ehrismann and Tucker, 2011). Numerous regulatory
FIGURE 3 | Tenascin-W (TNW) expression in human tumors. Examples of immunohistochemical analyses of TNW in various human tumors and adjacent normal
tissue are shown. Note that TNW is prominently expressed in the tumor stroma, often co-localizing with blood vessel markers (see kidney, brain, and lung cancer
pictures) and mostly not detectable in the corresponding normal tissue. vWF, von Willebrand factor; cd31, blood vessel marker; LN-MET, lymph node metastasis.
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mechanisms have been identified for tenascin-C, which include
regulation by patterning genes during development, growth
factors and inflammatory mediators, hypoxic conditions,
mechanical stress, activated signaling pathways, as well as
microRNAs (Tucker and Chiquet-Ehrismann, 2009b; Chiquet-
Ehrismann and Tucker, 2011; Chiovaro et al., 2015a). Several
of these stimuli might be relevant for the tumor-specific
expression of tenascin-C. For example, active Notch signaling
has been linked to tenascin-C expression during gliomagenesis
(Sivasankaran et al., 2009). Knowledge of tenascin-W regulation
remains sparse and mostly restricted to mouse and chicken
studies. BMP2, BMP7, and tumor necrosis factor (TNF) α
induce tenascin-W expression in cultured murine cells, such as
mouse embryonic fibroblasts, cranial fibroblasts, C2C12 cells,
and HC11 normal mammary gland epithelial cells (Scherberich
et al., 2004, 2005; Kimura et al., 2007; d’Amaro et al., 2012) and
primary chicken osteoblast cultures. However, this seems to be
different in human cells, in which none of the growth factors
tested are able to induce endogenous tenascin-W expression.
Only recently, TGFβ1 was identified as a first transcriptional
regulator of tenascin-W in the metastatic bone marrow niche.
De novo deposition of tenascin-W by stromal cells was induced
via cancer-mesenchymal cell interactions in a TGFβ1-dependent
manner (Chiovaro et al., 2015b). Clearly, more research is
required for the identification of additional differences (e.g.,
TGFβ vs. BMPs) or similarities (e.g., negative regulation by
glucocorticoids) in the control of tenascin-C and tenascin-W
genes, especially elucidating their abundant de novo expression
in neoplastic conditions.
Tenascin-W Promotes Tumor
Cell Migration
The first evidence that tenascin-W influences cancer cell
migration was provided in transwell migration assays using
murine mammary cells plated on inserts coated with mouse
tenascin-W. While the normal mouse mammary gland epithelial
cell line HC11 failed to migrate across filters coated with tenascin-
W, tenascin-W as substrata stimulated the migratory behavior
of the highly metastatic 4T1 mouse mammary cancer cell line
(Scherberich et al., 2005). This specific response to the presence
of tenascin-W was related to the expression of integrin α8, a
potential tenascin-W receptor (see above), in 4T1 cells and its
absence in HC11 cells (Scherberich et al., 2005). Confirming the
motility-promoting activity of tenascin-W, addition of soluble
human tenascin-W to the lower side of a transwell migration
chamber stimulated cell migration of T47D breast cancer
cells toward the fibronectin substratum (Degen et al., 2007).
Hence, presence of tenascin-W in the tumor microenvironment
stimulates migration of at least breast cancer cells.
Tenascin-W Promotes Angiogenesis
The observation that tenascin-W co-localizes with endothelial
cell markers in the tumor stroma of brain (Martina et al., 2010),
kidney, colon, breast, ovary, and prostate cancer (Brellier et al.,
2012b), but is completely absent in corresponding normal tissues,
encouraged additional studies to determine a possible function of
tenascin-W in promoting tumor angiogenesis. Indeed, presence
of tenascin-W induces an elongated morphology in human
umbilical vein endothelial cells (HUVEC) correlating with
increased motility, two characteristic features of angiogenic
endothelial cells (Martina et al., 2010). To gain further evidence
for a role of tenascin-W in stimulating angiogenesis, a collagen
gel-embedded spheroid-based in vitro angiogenesis assay was
performed. A significant induction of endothelial cell sprouts was
observed in HUVEC spheroids embedded in a collagen/tenascin-
W gel compared to collagen gels alone (Martina et al., 2010).
These data point toward an important role for tenascin-W in
stimulating tumor angiogenesis.
Promotion of Metastasis by Tenascin-W
Recent data suggest that tenascin-C represents an important
component of various physiological as well as pathological stem
cell niches, playing fundamental roles in stem cell maintenance
and renewal (Chiquet-Ehrismann et al., 2014). Since tenascin-
W often shares physiological and tumor-associated expression,
as well as functional similarities with tenascin-C, it was not
surprising to learn that tenascin-W is present in stem cell niches
as well (e.g., corneal limbus and whisker follicles; see above)
(Scherberich et al., 2004; Tucker et al., 2013). Similar to tenascin-
C, which is part of the lung-metastatic niche for breast cancer
cells (Oskarsson et al., 2011), evidence emerged recently that
tenascin-W is a component of the congenial metastatic niche
in breast cancer cells disseminating to bone (Chiovaro et al.,
2015b). After homing of breast cancer cells to bone marrow
the malignant cells secrete TGFβ1, which acts in a paracrine
fashion to modulate the bone marrow niche, including the de
novo deposition of tenascin-W. As a specific component of this
metastatic niche, tenascin-W promotes metastatic progression by
stimulating growth and migration of the cancer cells (Chiovaro
et al., 2015b). These data reveal that tenascin-W can be induced
in stem cell niches in the bone by breast cancer cell-secreted
factors, ultimately leading to an increased risk of bone metastasis.
This and other potential roles for tenascin-W in cancer are
summarized in Figure 4.
POTENTIAL TRANSLATIONAL USE
OF TENASCIN-W
Cancer Detection
Although tenascin-C and tenascin-W are often overexpressed in
tumor stroma, there is now good evidence that the expression of
tenascin-W is much more tumor-specific than the expression of
tenascin-C (Brellier et al., 2012b). Tenascin-C is readily expressed
in certain healthy tissues and it is well established that it can be re-
expressed under pathological conditions other than cancers, such
as inflammation, healing wounds, infections, and asthma (Orend
and Chiquet-Ehrismann, 2006; Brellier et al., 2009; Midwood
et al., 2016). Tenascin-W, however, mostly shows no detectable
expression in normal tissues adjacent to tumors (Degen et al.,
2007, 2008; Brellier et al., 2012b), and so far, there is no in situ
evidence that it can be induced under conditions other than
tumors. For instance, tenascin-W is neither detected in biopsies
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FIGURE 4 | Described functions of tenascin-W (TNW). As a matricellular protein, TNW regulates the interplay between stromal and epithelial cells, and between cells
and other extracellular matrix (ECM) components, thereby influencing cancer cell behavior and promoting tumor formation.
from patients with inflammatory bowel diseases displaying strong
tenascin-C expression (unpublished data) nor in healing wounds
in mice (Brellier et al., 2012a). Hence, its prominent and highly
tumor-specific expression establish tenascin-W as a potential
diagnostic tumor biomarker candidate. Tenascin-W can also be
detected in liquid biopsies, making it even more convenient and
attractive as a biomarker. Elevated levels of serum tenascin-W
have been reported in breast and colon cancer patients compared
to controls using a sensitive tenascin-W-specific sandwich ELISA
(Degen et al., 2008).
Prediction of Metastatic Potential
Tenascin-W expression is higher in mouse models of mammary
cancer that metastasize compared to non-metastasizing tumors
(Scherberich et al., 2005). Up to now, such a correlation was not
observed in human breast cancer where tenascin-W expression
is enriched in low-grade tumors (Degen et al., 2007). However,
in lung cancer, the average expression levels of tenascin-W
appear to correlate with tumor grade (Brellier et al., 2012b)
and in colorectal cancer, tenascin-W may correlate with the
aggressiveness of the disease. Mean serum tenascin-W levels
in non-metastatic colorectal cancer patients is 1.5-fold higher
in those patients suffering from recurrence compared to non-
recurrent patients (Degen et al., 2008). These data suggest
that tenascin-W might have potential value as a predictive
biomarker. Clearly, these initial studies are too small to draw
any conclusive conclusions. Nevertheless, these data warrant
more studies to determine the predictive value of tenascin-W in
certain malignancies.
Targeting Therapies
Given its tumor-specific expression and its proximity to blood
vessels, we speculate that tenascin-W might be used as a
potential candidate for identifying stromal areas with tumors
and as a potential target for therapies. Such therapies could
include selective delivery of anticancer medicine via tenascin-
W specific antibody-drug conjugates. Similar approaches are
successfully ongoing with tenascin-C-specific antibodies. In
particular, the F16 monoclonal human antibody specifically
recognizing the alternatively spliced A1 domain of tenascin-
C is being evaluated in clinical trials in combination with
approved anti-tumor drugs in patients with solid tumors and
metastatic breast cancer (Catania et al., 2015). Since tenascin-
W seems to a be a more specific tumor marker than tenascin-C
(Brellier et al., 2012b), tenascin-W might represent an additional
tumor antigen that could be used as target for antibody-
based therapies.
Diverse pro-tumorigenic activities have been attributed to
tenascin-W in the tumor stroma. Hence, specifically knocking-
down tenascin-W via RNA interference approaches in tumors
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could interfere with various crucial stages during the malignant
progression and could be beneficial for cancer patients. In this
regard, it is noteworthy that such strategies are being developed
for tenascin-C. Tenascin-C expression was successfully targeted
in aggressive brain tumors with a double stranded RNA
homologous to tenascin-C triggering its degradation. Glioma
patients treated with such an approach benefited from a better
quality of life as well from an increase in overall survival.
However, the treatment only provided a very short survival
advantage (Wyszko et al., 2008).
CONCLUSION AND
FUTURE DIRECTIONS
Since its discovery in zebrafish 21 years ago (Weber et al.,
1998), we have gained significant insight into the structure,
evolution, function, and expression of tenascin-W, the final
member of the tenascin family. Tenascin-W appears to have
evolved together with bone, and a phylogenetically conserved site
of tenascin-W expression is at sites of osteogenesis. Tenascin-W
is also part of certain adult stem cell niches and is prominent
in tumor stroma. In contrast to tenascin-C, tenascin-W is
generally absent from normal adult tissue. Cell cultures studies
reveal that tenascin-W is an adhesion modulatory protein that
can promote bone development, angiogenesis, cell adhesion
and cell migration. These observations may be related to the
widespread expression of tenascin-W in solid tumors, where
tenascin-W may also promote angiogenesis, cell adhesion and
cell migration. Whether or not this information will lead to
the development of novel cancer diagnosis opportunities or
even intervention therapies remains speculative at this point.
To make use of tenascin-W as a potential therapeutic entry
point we first need to greatly advance our understanding
about the impact of the tumor microenvironment on disease
progression and about the complexity and multi-functionality
of tenascin-W. Compared with tenascin-C, relatively little is
known about tenascin-W, but there are some clear directions
for future research. The tenascin-W promoter, for example,
still needs serious attention. In addition, while the adhesion
modulatory properties of tenascin-C have been described in
detail, the molecular mechanisms of how tenascin-W affects
adhesion remain elusive. For instance, is tenascin-W able to
bind to fibronectin, which would be similar to tenascin-C,
and which integrins and signaling pathways are involved in
regulating the adhesion-modulating characteristics of tenascin-
W? Surprisingly, no one has published a characterization of the
tenascin-W knockout mouse. This may be partly due to the
legacy of the tenascin-C knockout mouse, which was notorious
for having a “null phenotype” and the possibility that tenascin-
C and tenascin-W might compensate for each other’s absence in
certain tissues. However, more detailed studies of the tenascin-
C knockout mouse revealed significant defects in behavior that
are likely related to abnormal neural stem cell niches, as well
as other phenotypes related to abnormal responses to trauma
and inflammation. Similarly, detailed studies of the tenascin-W
knockout mouse may also prove fruitful.
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